Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

887
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
887
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

163
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
163
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

538
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
538
Parentral Nutrition: Centeral and Peripheral Parental Nutrition01:27

Parentral Nutrition: Centeral and Peripheral Parental Nutrition

406
Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
406
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

69
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heparin vs Saline Infusion For Maintaining the Patency of Arterial Catheters in Children: Author's Reply.

Indian pediatrics·2024
Same author

Sex-specific differences in systemic immune responses in MIS-C children.

Scientific reports·2024
Same author

Heparin vs Saline Infusion to Maintain Patency of Arterial Catheters in Children: A Randomized, Double-Blind, Noninferiority Trial.

Indian pediatrics·2024
Same author

Active surveillance for carbapenem resistant enterobacteriaceae (CRE) using stool cultures as a method to decrease CRE infections in the pediatric intensive care unit (PICU).

Indian journal of medical microbiology·2023
Same author

Levels of Complement Components in Children With Acute COVID-19 or Multisystem Inflammatory Syndrome.

JAMA network open·2023
Same author

Role of matrix metalloproteinases in multi-system inflammatory syndrome and acute COVID-19 in children.

Frontiers in medicine·2022

Related Experiment Video

Updated: Nov 2, 2025

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.5K

Peripheral Inotropes in Critically Ill Children: Is It Safe?

Ravi K Mooli1, Kalaimaran Sadasivam1

  • 1Kanchi Kamakoti CHILDS Trust Hospital, Chennai, Tamil Nadu, India.

Global Pediatric Health
|June 9, 2021
PubMed
Summary

Peripheral inotropes are vital for pediatric intensive care. This study found that peripheral vasoactive inotrope administration in children has a very low risk of extravasation injury (3%), suggesting safe use in diluted concentrations.

Keywords:
PICUcentral cathetersextravasationinotropesperipheral cathetersvasoactive medications

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.4K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Related Experiment Videos

Last Updated: Nov 2, 2025

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
12:43

Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption

Published on: August 16, 2016

20.5K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.4K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Area of Science:

  • Pediatric critical care medicine
  • Pharmacology
  • Vascular access

Background:

  • Pediatric intensive care units (PICUs) frequently require inotropes for critically ill children.
  • Central venous access may be delayed or unavailable, especially in low- and middle-income countries (LMICs).
  • Peripheral venous access is often used for vasoactive medication administration in these settings.

Purpose of the Study:

  • To describe the role and safety of peripheral vasoactive inotropes in pediatric patients.
  • To evaluate the incidence of complications, specifically extravasation injury, associated with peripheral inotrope administration.

Main Methods:

  • Retrospective data collection from children requiring peripheral vasoactive medications.
  • Data collected at two time points, including pre-COVID era and during the COVID pandemic.
  • Analysis of the use and complications of peripheral vasoactive medications.

Main Results:

  • Eighty-four children received peripheral vasoactive medications (51 pre-COVID, 33 during COVID).
  • Only 3% (3/84) of children experienced extravasation injury.
  • All children who developed extravasation injury recovered completely.

Conclusions:

  • Peripheral inotrope infusion in children is associated with a very low rate of extravasation injury (3%).
  • Diluted concentrations of peripheral vasoactive inotropes can be safely administered to pediatric patients.
  • This approach offers a viable option for hemodynamic support when central access is limited.